1. Effect of bronchodilators in healthy individuals receiving lumacaftor/ivacaftor combination therapy 
Gautham Marigowda, Fang Liu, David Waltz 
Journal of Cystic Fibrosis 
Volume 16, Issue 2, Pages (March 2017)
DOI: /j.jcf
Copyright © 2016 The Authors Terms and Conditions

2. Fig. 1
Percent predicted FEV1 before and after LUM/IVA administration in the absence of LABD (period 1).
Data are mean ppFEV1 during period 1 and error bars indicate standard error.
FEV1, forced expiratory volume in 1s; LUM/IVA, lumacaftor/ivacaftor; SABD, short-acting bronchodilator; SE, standard error.
Journal of Cystic Fibrosis  , DOI: ( /j.jcf )
Copyright © 2016 The Authors Terms and Conditions

3. Fig. 2
Percent predicted FEV1 before and after LUM/IVA administration in the presence of LABD (periods 2 and 3).
Data are mean ppFEV1 during periods 2 and 3 (average) and error bars indicate standard error.
FEV1, forced expiratory volume in 1s; LABD, long-acting bronchodilator; LUM/IVA, lumacaftor/ivacaftor; SABD, short-acting bronchodilator; SE, standard error.
Journal of Cystic Fibrosis  , DOI: ( /j.jcf )
Copyright © 2016 The Authors Terms and Conditions

4. Fig. 3
Absolute change in ppFEV1 at 4h post LUM/IVA in the absence of a bronchodilator (day 1).
Waterfall plot showing the absolute change in ppFEV1 at 4h post LUM/IVA on day 1 in the absence of a bronchodilator. Each bar represents data for an individual subject.
LUM/IVA, lumacaftor/ivacaftor; ppFEV1, percent predicted forced expiratory volume in 1s.
Journal of Cystic Fibrosis  , DOI: ( /j.jcf )
Copyright © 2016 The Authors Terms and Conditions